British pharmaceutical giant GlaxoSmithKline has agreed to pay $3 billion in civil and criminal fines for promoting two drugs, Paxil and Wellbutrin, for unapproved uses, and failing to report key ...

On Monday morning, GlaxoSmithKline and Verily Life Sciences, which is owned by Google’s parent, Alphabet, formed a new company that will fight diseases by targeting electrical signals in the body. The ...

Glaxo (GSK) delivered earnings and revenue surprises of +17.46% and +3.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Artificial intelligence research experienced a renaissance in the last twenty years as a result in part of greater computing power, the rise of the graphics processing unit, or GPU. Now, novel AI ...

This morning, GlaxoSmithKline announced a $3 billion criminal settlement with the Department of Justice to settle accusations that it didn't tell regulators about safety problems with an infamous drug ...

For the second time in less than a year, GlaxoSmithKline (GSK) is reworking promotional practices in order to boost prescriptions, and its latest move will provide greater incentives for its sales ...

Like weeds in a prized flower bed, problems around misconduct and corruption can quickly spread. So it is proving for GlaxoSmithKline, which has confirmed the U.K.'s Serious Fraud Office has started a ...

LONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported third-quarter earnings of $2.71 billion. The London-based company said it had net income of $1.34 per share. Earnings, adjusted for ...

GlaxoSmithKline plc GSK reported third-quarter 2021 adjusted earnings of $1.01 per American depositary share (“ADS”), comfortably beating the Zacks Consensus Estimate of 80 cents. Adjusted earnings ...

The best to hope for, sometimes, is simply that the worst is over. Shares in GlaxoSmithKline, the laggard of the European pharmaceutical sector last year, rose on Wednesday after it reported ...

With over 5 million customers, genetic testing firm 23andMe sits on a trove of human data it believes can help drugmakers develop treatments more efficiently in an industry where 90% of medicines on ...